in this issue
Markets :: Fine Chemicals/Biotech :: Pharmaceutical ingredients
Pharma/fine chemicals roundup—21 October 2013
4:49 AM MDT | October 21, 2013 | Deepti Ramesh
AstraZeneca acquires ADC technology firm Spirogen AstraZeneca (London) says that its biologics R&D arm, MedImmune (Gaithersburg, MD), has acquired Spirogen (London), a privately held biotech company focused on antibody-drug conjugate (ADC) technology for use in oncology. MedImmune has also entered into a collaboration agreement with ADC Therapeutics (Lausanne, Switzerland) to jointly develop two of ADC Therapeutics’ ADC programs in preclinical development, AstraZeneca says. MedImmune will also make an equity investment in ADC Therapeutics, which has an...
This information is only available to Chemical Week subscribers.
Forgot your user ID or password?
Not an IHS Chemical Week member yet?
Here's why you should be:
100% Satisfaction Guarantee